CN117320556A - 富含免疫球蛋白的含乳清蛋白的产品 - Google Patents
富含免疫球蛋白的含乳清蛋白的产品 Download PDFInfo
- Publication number
- CN117320556A CN117320556A CN202280029645.0A CN202280029645A CN117320556A CN 117320556 A CN117320556 A CN 117320556A CN 202280029645 A CN202280029645 A CN 202280029645A CN 117320556 A CN117320556 A CN 117320556A
- Authority
- CN
- China
- Prior art keywords
- whey
- whey protein
- containing product
- protein
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 76
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 67
- 235000021119 whey protein Nutrition 0.000 title claims abstract description 43
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 33
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 33
- 229940072221 immunoglobulins Drugs 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000000047 product Substances 0.000 claims abstract description 29
- 239000005018 casein Substances 0.000 claims abstract description 27
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000021240 caseins Nutrition 0.000 claims abstract description 27
- 235000013336 milk Nutrition 0.000 claims abstract description 24
- 210000004080 milk Anatomy 0.000 claims abstract description 24
- 239000008267 milk Substances 0.000 claims abstract description 24
- 239000012528 membrane Substances 0.000 claims abstract description 22
- 239000012465 retentate Substances 0.000 claims abstract description 15
- 239000011347 resin Substances 0.000 claims abstract description 14
- 229920005989 resin Polymers 0.000 claims abstract description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- 238000009295 crossflow filtration Methods 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 10
- 238000012434 mixed-mode chromatography Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000012466 permeate Substances 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 4
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 4
- 102000008192 Lactoglobulins Human genes 0.000 claims abstract description 4
- 108010060630 Lactoglobulins Proteins 0.000 claims abstract description 4
- 239000011148 porous material Substances 0.000 claims abstract description 4
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 4
- 239000005862 Whey Substances 0.000 claims description 33
- 235000013351 cheese Nutrition 0.000 claims description 17
- 235000013350 formula milk Nutrition 0.000 claims description 17
- 235000018102 proteins Nutrition 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 235000020218 follow-on milk formula Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 235000020209 toddler milk formula Nutrition 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 235000021277 colostrum Nutrition 0.000 description 11
- 210000003022 colostrum Anatomy 0.000 description 11
- 235000020247 cow milk Nutrition 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 7
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- 210000003165 abomasum Anatomy 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000012539 chromatography resin Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001471 micro-filtration Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- -1 acidulants (e.g. Chemical compound 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000182 glucono-delta-lactone Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012433 multimodal chromatography Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 238000012441 weak partitioning chromatography Methods 0.000 description 1
- 239000011155 wood-plastic composite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
- A23C9/1465—Chromatographic separation of protein or lactose fraction; Adsorption of protein or lactose fraction followed by elution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Water Supply & Treatment (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Dairy Products (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
披露了用于生产富含免疫球蛋白的含乳清蛋白的产品的方法,所述方法包括以下步骤:(i)使用截留分子量(MWCO)为500‑1000kDa、优选500‑800kDa或孔径为50‑100nm、优选50‑80nm的膜对酪蛋白减少的乳进行错流过滤,从而获得UF渗余物和富含乳糖、盐、α‑乳白蛋白和β‑乳球蛋白的渗透物,以及(ii)对所述UF渗余物进行混合模式层析,其中免疫球蛋白粘附到树脂上并随后被洗脱以形成所述富含免疫球蛋白的含乳清蛋白的产品。
Description
本发明涉及具有高免疫球蛋白含量的含乳清蛋白的产品、其生产和用途。
在哺乳动物后代能够消化其他来源的食物之前,乳是它们的唯一营养源。所有泌乳动物的初乳和乳都含有免疫球蛋白(Ig),免疫球蛋白为后代提供针对微生物病原体和毒素的免疫保护,并保护乳腺免受感染。牛乳和人乳中主要类别的免疫球蛋白是IgG、IgA和IgM,这些免疫球蛋白在结构和生物活性上有所不同。IgG可细分为IgG1和IgG2。在人乳中,主要的Ig是IgA。人母乳含有约85wt%-90wt%的IgA、约2wt%-3wt%的IgG、以及约8wt%-10wt%的IgM(J.A.Cakebread等人,J.Agric.Food Chem.[农业食品化学杂志],63(2015)7311-7316)。人母乳中的总Ig浓度是牛乳中Ig含量的约1.5倍(J.A.van Neerven等人,J.Allergy Clin.Immunol.[变态反应与临床免疫学杂志],2012年10月,853-858)。
另一方面,在牛乳中,主要的Ig是IgG。成熟牛乳含有约80wt%的IgG(绝大多数是IgG1)、约10wt%的IgM、以及约10%的IgA。牛初乳的Ig含量比成熟牛乳的Ig含量高得多:初乳的总蛋白含量的70%-80%是Ig,而在成熟牛乳中,Ig仅占总蛋白含量的1wt%-2wt%。
通过将至少一种乳清蛋白源、至少一种乳(酪蛋白)蛋白源、至少一种脂质源、至少一种碳水化合物源、以及维生素和矿物质组合来制备婴儿配方乳。牛乳是这些蛋白质、碳水化合物、脂质和维生素的应用来源之一。
人们一直希望生产与人母乳尽可能相似的婴儿配方乳。因此,为实现此目标,人们希望增加婴儿配方乳中的活性免疫球蛋白含量。
通常,通过将乳与至少一种乳清蛋白源、至少一种脂质源、至少一种碳水化合物源、以及维生素和矿物质组合来制备婴儿配方乳。
乳清蛋白源优选地选自乳清蛋白浓缩物(WPC)和血清蛋白浓缩物(SPC)。这两种产品都是将脱脂乳分离成富含酪蛋白和富含乳清蛋白的级分的结果;通过凝乳(即干酪制作)、酸化或微滤。免疫球蛋白主要存在于乳血清/乳清相而非酪蛋白胶束相中,因此被认为是乳清蛋白。
乳清蛋白浓缩物(WPC)常规地通过对酸性乳清或干酪乳清进行超滤和/或反渗透以及任选地去矿化获得。通过超滤,大部分的水、乳糖和灰分从产物中去除,从而将乳清蛋白浓缩。反渗透可用于去除水并进一步浓缩WPC。血清蛋白浓缩物(SPC)也是浓缩的乳清蛋白产物,与WPC的不同之处在于乳清级分的来源。与酸性乳清或干酪乳清相反,SPC中的乳清蛋白来自于脱脂乳的微滤;它们通常被称为天然乳清。所述微滤产生浓缩的酪蛋白渗余物(retentate)级分和含有大部分乳清蛋白作为渗透物(permeate)级分的血清级分。常规地,然后对这种渗透物级分进行超滤和/或反渗透以去除乳糖、灰分和水。
这些常规方法中使用的UF膜的截留分子量(MWCO)在5-10kDa的范围内。因此,水、乳糖和矿物质通过膜,而蛋白质浓缩在渗余物中。
基于总乳清蛋白,常规WPC和SPC的免疫球蛋白含量低于6wt%。这与成熟牛乳中的含量相当,这意味着常规的WPC制备不会导致Ig含量的显著富集。
EP 0 320 152披露了一种使用两种不同工艺生产富含免疫球蛋白的WPC的方法。
在第一种工艺中,使用截留分子量(MWCO)为500kDa的膜对乳清进行超滤。
在第二种工艺中,首先对乳清进行阴离子交换层析。与其他乳清蛋白相反,大多数免疫球蛋白不与阴离子交换树脂结合,因此形成流出物。然后使用MWCO为500kDa的膜对该流出物进行超滤。
使用阴离子交换树脂的WPC的Ig富集也披露在WO 01/41584中;实例4。
这些程序的缺点是阴离子交换树脂不结合免疫球蛋白,而是结合更丰富的其他乳清蛋白。这导致了层析方法的高容量需求。
H.J.Heidebrecht等人,J.Chromatogr.A[层析杂志A]1562(2018)59-68披露了使用混合模式层析从牛初乳乳清中分离牛IgG。混合模式层析基于疏水相互作用和阳离子交换的组合。
混合模式层析树脂结合免疫球蛋白而不是大多数其他乳清蛋白,这意味着与阴离子交换层析相比需要的层析容量更低。
然而,仍然希望进一步改善层析容量并进一步改善获得的免疫球蛋白的纯度。
本发明的方法满足了该目的,该方法涉及在层析步骤之前使用特定膜进行错流过滤步骤。这样可以进一步增加层析树脂的结合能力,即每个周期中每树脂体积的免疫球蛋白量。先前的过滤步骤减少了可能与免疫球蛋白竞争结合树脂的乳清蛋白的数量,从而提高了免疫球蛋白与树脂的结合能力和传质。
因此,本发明涉及提供具有高于常规含乳清蛋白的产品(例如WPC和SPC)的免疫球蛋白含量的含乳清蛋白的产品,以及涉及导致总Ig含量相对于总蛋白富集至少10倍、优选地至少15倍、最优选地至少20倍的方法。基于总蛋白,根据本发明的含乳清蛋白的产品含有至少40wt%、优选地50wt%-80wt%的IgG。
含乳清蛋白的产品的总蛋白含量通过BCA法测定,如下所述:R.A.Brown等人,Analytical Biochemistry[分析生物化学],第180卷(1),1989年7月,136-139。该IgG含量使用基于RP-HPLC的方法测定,如下所述:D.F.Elgar等人,Journal of Chromatogeraphy A[层析杂志A],第878卷,2000,183-196。
含乳清蛋白的产品通过包括以下步骤的方法制备:
(i)使用截留分子量(MWCO)为500-1000kDa、优选500-800kDa或孔径为50-100nm、优选50-80nm的膜对酪蛋白减少的乳进行错流过滤,从而获得UF渗余物和富含乳糖、盐、α-乳白蛋白和β-乳球蛋白的渗透物,以及
(ii)对所述UF渗余物进行混合模式层析,其中免疫球蛋白粘附到树脂上并随后被洗脱以形成所述富含免疫球蛋白的含乳清蛋白的产品。
术语“酪蛋白减少的乳”是指经受减少酪蛋白的方法的任何乳级分,该方法是例如酪蛋白沉淀(产生酸性乳清)、干酪制作方法(产生干酪乳清)或微滤以分离酪蛋白和血清蛋白(产生天然乳清)。因此,酪蛋白减少的乳优选地涉及酸性乳清、干酪乳清或天然乳清。更优选地,它是指酸性乳清或干酪乳清。
乳优选地为牛乳,更优选地为成熟牛乳。尽管牛初乳含有比成熟牛乳多得多的免疫球蛋白,但使用来自牛初乳的乳清来生产富含免疫球蛋白的含乳清蛋白的产品仍非选择。首先,初乳的组分(例如,其高浓度的乳清蛋白)使得其倾向于沉淀在热交换器和蒸发器的表面上,从而导致它们的清洁和维护方面出现问题。此外,初乳的使用引发了伦理问题,因为它剥夺了新生小牛在其生命最初几天的必要营养。
在本发明的内容中,成熟牛乳是牛乳而非初乳。初乳是产犊后前三天的乳。与成熟牛乳相比,初乳具有更高水平的脂肪、乳清蛋白(包括Ig)、维生素和矿物质,以及更低水平的乳糖和酪蛋白。
酸性乳清是通过使乳(优选地在脱脂和巴氏灭菌之后)经受酪蛋白沉淀方法来生产的。这种酪蛋白沉淀涉及添加酸以诱导酪蛋白凝固,从而产生酸性酪蛋白级分(酪蛋白凝块)和酸性乳清级分。酸优选地选自HCl、H2SO4和柠檬酸。
例如,可以向脱脂乳中添加1M H2SO4,在40℃-45℃下充分搅拌,直至达到4.3-4.6范围内的pH。搅拌酸化的乳直至凝块完全形成。然后通过例如袋式过滤或离心从乳清中除去凝块。
干酪乳清是通过使乳(优选地在脱脂和巴氏灭菌之后)经受干酪制作方法来生产的。该干酪制作方法优选地涉及添加凝固剂和酸化剂,并使其凝固以获得富含酪蛋白的级分(干酪或干酪前体)和乳清级分。
酸化的目标pH优选地在4.8至5.7、更优选地在4.9至5.5的范围内。合适的酸化剂包括将乳糖转化为乳酸的发酵剂(细菌酸化剂)、酸、酸味剂(例如葡萄糖酸δ内酯或GDL)以及这些中的两种或更多种的组合。最常见的发酵剂包括嗜热型发酵剂,典型地来自CSK公司、科汉森公司(Chr.Hansen)或杜邦公司(DuPont)的发酵剂。科汉森公司的嗜热型发酵剂包括冷冻培养物STI-02、STI-03、STI-04和STI-06,以及冻干培养物STI-12、STI-13和STI-14。也可以使用嗜温型发酵剂。
合适的凝固剂在本领域是已知的,并且包括例如小牛皱胃酶、发酵产生的皱胃酶和微生物皱胃酶。小牛皱胃酶的实例包括CSK公司生产的Kalase和科汉森公司生产的Naturen。发酵产生的皱胃酶的实例包括DSM公司的Fromase和CSK公司的Milase。微生物皱胃酶的实例为科汉森公司的Chy-Max和DSM公司的Maxiren。其他凝固剂包括胃蛋白酶和植物来源的各种蛋白水解酶。
基于总蛋白,酪蛋白减少的乳的总IgG含量通常在2.5wt%-10wt%、优选地2.5wt%-5.0wt%的范围内。通过测定总蛋白含量并减去该总蛋白含量中的非蛋白氮(NPN)和酪蛋白含量来测定酪蛋白减少的乳的总蛋白含量;全部通过熟知的凯氏定氮法(Kjeldahl method)(换算系数6.38)来测定。酪蛋白减少的乳的IgG含量可以使用ELISA定量装置进行测定,如下所述:R.L.Valk-Weeber,T.Eshuis-de Ruiter,L.Dijkhuizen,和S.S.van Leeuwen,International Dairy Journal[国际乳品杂志],第110卷,2020年11月,104814。
使用截留分子量(MWCO)为500-1000kDa、优选500-800kDa或孔径为50-100nm、优选50-80nm的膜对酪蛋白减少的乳进行错流过滤,从而获得富含乳糖、盐、α-乳白蛋白和β-乳球蛋白的渗透物,以及富含免疫球蛋白(相对于总蛋白)的渗余物。
该过滤步骤用于增加流的免疫球蛋白浓度和纯度,以改善层析树脂的结合能力和下一步骤产物的纯度。
合适的错流过滤膜类型包括螺旋卷式膜、陶瓷膜和中空纤维膜。考虑到价格和在大规模方法中的适用性,优选螺旋卷式膜。
该膜可以由各种类型的聚合物构建,例如聚砜(PS)、(改性)聚醚砜、聚偏二氟乙烯(PVDF)、聚丙烯腈(PAN)、乙酸纤维素(CA)和聚丙烯(PP)。
穿过膜的跨膜压力(TMP)优选地在0.25-1.5巴、更优选地0.25-1.0巴、最优选地0.25-0.5巴的范围内。
错流过滤步骤在10℃-15℃或50℃-55℃、优选地50℃-55℃的温度范围内进行。
对于螺旋卷式膜,错流流速优选地在0.1-0.3m/s、更优选地0.2-0.3m/s、最优选地0.25-0.3m/s的范围内;对于陶瓷膜,错流流速为5-7m/s,最优选地6-7m/s;对于中空纤维膜,错流流速为1-3m/s,更优选地2-3m/s,最优选地2.5-3m/s。
为了进一步提高免疫球蛋白的纯度,需要进行渗滤。
可以以固定的VCF对酪蛋白减少的乳进行浓缩或渗滤。
渗余物优选具有约中性pH。也就是说,pH优选地在6.0至8.0、更优选地在6.5至7.5的范围内。如果pH尚未在此范围内,可以通过添加酸或碱来调节pH。
然后对渗余物进行特殊类型的层析,我们在本文中将其称为混合模式层析或多元模式层析。这种类型的层析涉及疏水相互作用和阳离子相互作用的组合,也称为疏水性电荷诱导层析(HCIC)。在中性pH下,蛋白质与树脂的结合是通过疏水相互作用进行的;在低pH下,洗脱机制基于静电排斥。
优选的混合模式树脂是MEP HyperCelTM,其由与4-巯基-乙基-吡啶(4-MEP)配体连接的多孔纤维素基质组成。在pKa为4.8的情况下,4-MEP配体在中性pH下不带电荷,因此免疫球蛋白的吸附主要通过疏水相互作用实现。
其他合适的混合模式树脂为HEA HypercelTM,其含有己胺配体;HCX层析树脂,其含有强离子性磺基基团、弱离子性羧基基团、疏水相互作用的苯基基团以及氢结合的羟基和胺基基团;Nuvia cPrime,一种疏水性阳离子交换树脂;和CaptoTM MMC,一种多峰弱阳离子交换树脂。
随后使用水溶液(优选pH为2.0-7.0、更优选2.0-6.0、甚至更优选3.0-5.0、并且最优选4.0-5.0)从树脂中洗脱免疫球蛋白。优选地,使用缓冲溶液来达到该pH。可以使用任何类型的缓冲液。
如果需要,可以使所得含免疫球蛋白的流出物经受进一步的处理步骤。此类处理步骤的实例是:去矿化,例如通过超滤和/或渗滤;浓缩,例如通过蒸发或冷冻浓缩;和干燥,例如喷雾干燥或冷冻干燥。
基于总蛋白,根据本发明并通过根据权利要求1所述的方法生产的含乳清蛋白的产品优选地包含至少40wt%、优选地50wt%-80wt%的IgG。如上所述,该产品的总蛋白含量通过BCA法测定,如下所述:R.A.Brown等人,Analytical Biochemistry[分析生物化学],第180卷(1),1989年7月,136-139;IgG含量使用基于RP-HPLC的方法测定,如下所述:D.F.Elgar等人,Journal of Chromatogeraphy A[层析杂志A],第878卷,2000,183-196。
可以进一步浓缩、去矿化、和/或(喷雾)干燥由本发明的方法得到的含乳清蛋白的产品以制备粉末状产品。
根据本发明的含乳清蛋白的产品特别适合用作生产营养组合物、特别是配方乳的成分。配方乳选自下组:婴儿配方乳、较大婴儿配方乳和成长型配方乳。因此,本发明进一步涉及营养组合物、典型地用于儿童的营养组合物,例如配方乳、特别是婴儿配方乳、较大婴儿配方乳或成长型配方乳。
营养组合物、特别是配方乳,可通过将WPC与至少一种脂质源、碳水化合物源、维生素和矿物质以及任选的其他乳品和蛋白质源组合来制备。
脂质源可以是适合在配方乳中使用的任何脂质或脂肪。优选的脂肪源包括乳脂肪、红花籽油、蛋黄脂质、菜籽油、橄榄油、椰子油、棕榈仁油、大豆油、鱼油、棕榈油酸、高油酸葵花籽油和高油酸红花籽油、以及含有长链多不饱和脂肪酸的微生物发酵油。在一个实施例中,使用无水乳脂肪。脂质源也可以是源自这些油例如棕榈油精、中链甘油三酯,和脂肪酸例如花生四烯酸、亚油酸、棕榈酸、硬脂酸、二十二碳六烯酸、亚麻酸、油酸、月桂酸、癸酸、辛酸、己酸等的酯的级分形式。也可以添加少量的含有大量预先形成的花生四烯酸和二十二碳六烯酸的油,如鱼油或微生物油。脂肪源优选地具有约5∶1至约15∶1,例如约8∶1至约10∶1的n-6与n-3脂肪酸比率。在特定方面,婴儿配方乳包含油混合物,该油混合物包含被酯化为三酰甘油的棕榈酸,例如其中在三酰甘油的sn-2位置被酯化的棕榈酸的量为按重量计20%至60%的总棕榈酸,并且在三酰甘油的sn-1/sn-3位置被酯化的棕榈酸的量为按重量计40%至80%的总棕榈酸。
优选地存在于配方乳中的维生素和矿物质的实例为维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、烟酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、锰、氯化物、钾、钠、硒、铬、钼、牛磺酸和L-肉碱。矿物质通常以盐的形式添加。
优选地存在于配方乳中的碳水化合物的实例为乳糖、不可消化的寡糖(例如半乳寡糖(GOS)和/或果寡糖(FOS))和人乳寡糖(HMO)。
如有必要,营养组合物可含有乳化剂和稳定剂,如大豆卵磷脂、单甘油酯和二甘油酯的柠檬酸酯等。营养组合物也可含有可能具有有益效果的其他物质,例如乳铁蛋白、核苷酸、核苷等。
图
图1展示了实例1-3的层析步骤期间IgG的穿透。它示出了流过柱而非与树脂结合的IgG的百分比。流过柱的IgG的水平越低,即穿透越低,结合能力越高。
实例
对比实例1
将具有10wt%干物质的干酪乳清用作起始材料。将pH调整到7.0。将已知量(2.51)的所述干酪乳清上样至混合模式层析柱(MEP-Hypercel,50ml树脂),流速为4个批体积/小时(BV/hr),等于3.3ml/min。在上样和随后的冲洗后,用(1)pH 6的0.050mol/l MES(2-(N-吗啉代)乙磺酸)缓冲液、(2)pH 4.5的0.05mol/l乙酸钠缓冲液和(3)pH 2.7的0.1mol/l甘氨酸-HCl缓冲液逐步洗脱吸附的蛋白质。当树脂暴露在乙酸盐缓冲液(50mM,pH=4,5)中、使用4BV/hr流速时,绝大多数吸附的蛋白质从柱中释放出来。
使用BCA和RP-HPLC对获得的级分(起始材料、穿透物和吸附物)进行蛋白质和IgG含量分析。获得的结果示于表1中。
图1示出了穿透曲线,该曲线展示了流过而非与树脂结合的Ig浓度。
对比实例2
重复对比实例1,不同之处在于进行层析前,首先将干酪乳清稀释至干物质含量为6wt%,然后使用TAMI 8kDa陶瓷膜进行错流过滤方法。应用的错流流速为151/min;跨膜压力为1.5巴。这导致渗余物的浓缩系数为4。
将所述渗余物的pH调节至7.0,然后根据实例1进行层析。
获得的结果示于表1中;穿透曲线示于图1中。
实例3
重复对比实例2,不同之处在于用500kD螺旋卷式膜进行错流过滤。总共有400kg的乳清在浓缩物侧循环。以80l/min的错流流速和0.5巴的TMP开始过滤。将产物浓缩至最终体积约为331,并且将获得的浓缩物进行1x33 1份的渗滤。
将所述渗余物的pH调节至7.0,然后根据实例1进行层析。
获得的结果示于表1中;穿透曲线示于图1中。显示了与实例1和2的方法相比,实例3的方法导致显著降低的IgG穿透(即损失)、更高的IgG纯度和更高的产率。因此,对比不过滤的用8kDa膜进行超滤,在层析步骤之前进行根据本发明的错流过滤改善了结合能力、IgG纯度和产率。
表1
Claims (12)
1.一种用于生产富含免疫球蛋白的含乳清蛋白的产品的方法,所述方法包括以下步骤:
(i)使用截留分子量(MWCO)为500-1000kDa、优选500-800kDa或孔径为50-100nm、优选50-80nm的膜对酪蛋白减少的乳进行错流过滤,从而获得UF渗余物和富含乳糖、盐、α-乳白蛋白和β-乳球蛋白的渗透物,以及
(ii)对所述UF渗余物进行混合模式层析,其中免疫球蛋白粘附到树脂上并随后被洗脱以形成所述富含免疫球蛋白的含乳清蛋白的产品。
2.根据权利要求1所述的方法,其中该酪蛋白减少的乳选自酸性乳清、干酪乳清和天然乳清,优选地选自酸性乳清和干酪乳清。
3.根据权利要求1或2所述的方法,其中对步骤(ii)中形成的该含乳清蛋白的产品进行浓缩和/或干燥步骤。
4.根据前述权利要求中任一项所述的方法,其中基于总乳清蛋白,该含乳清蛋白的产品包含至少40wt%、优选地50wt%-80wt%的IgG。
5.根据前述权利要求中任一项所述的方法,其中进行混合模式层析的该渗余物的pH在6.0-8.0的范围内,优选地在6.5-7.5的范围内。
6.根据前述权利要求中任一项所述的方法,其中进行错流过滤前,基于总蛋白,该酪蛋白减少的乳的IgG含量在2.5wt%-10wt%、优选地2.5wt%-5.0wt%的范围内。
7.根据前述权利要求中任一项所述的方法,其中步骤(i)中使用的该膜是螺旋卷式膜。
8.一种可以根据前述权利要求中任一项所述获得的含乳清蛋白的产品。
9.根据权利要求8所述的含乳清蛋白的产品,其包含基于总乳清蛋白,至少40wt%、优选地50wt%-80wt%的IgG。
10.一种营养组合物,其包含根据权利要求8或9所述的含乳清蛋白的产品。
11.根据权利要求10所述的营养组合物,其中该营养组合物选自婴儿配方乳、较大婴儿配方乳和成长型乳。
12.一种用于生产根据权利要求10或11所述的营养组合物的方法,该方法通过将根据权利要求8或9所述的含乳清蛋白的产品与至少一种脂肪源、碳水化合物源、维生素和矿物质以及任选地另外的乳品和/或蛋白质源组合来进行。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21171274.0 | 2021-04-29 | ||
EP21171274 | 2021-04-29 | ||
PCT/EP2022/061383 WO2022229342A1 (en) | 2021-04-29 | 2022-04-28 | Whey protein-containing product enriched in immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117320556A true CN117320556A (zh) | 2023-12-29 |
Family
ID=75746308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280029645.0A Pending CN117320556A (zh) | 2021-04-29 | 2022-04-28 | 富含免疫球蛋白的含乳清蛋白的产品 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240188579A1 (zh) |
EP (1) | EP4329501A1 (zh) |
JP (1) | JP2024517153A (zh) |
CN (1) | CN117320556A (zh) |
AU (1) | AU2022263624A1 (zh) |
BR (1) | BR112023021397A2 (zh) |
WO (1) | WO2022229342A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8729031D0 (en) | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
CA2393270A1 (en) | 1999-12-08 | 2001-06-14 | Massey University | Process for separation of whey proteins using a novel anion exchanger |
US20140234506A1 (en) * | 2013-02-18 | 2014-08-21 | Wisconsin Alumni Research Foundation | Methods and compositions for protein concentration |
-
2022
- 2022-04-28 JP JP2023565603A patent/JP2024517153A/ja active Pending
- 2022-04-28 EP EP22726104.7A patent/EP4329501A1/en active Pending
- 2022-04-28 AU AU2022263624A patent/AU2022263624A1/en active Pending
- 2022-04-28 WO PCT/EP2022/061383 patent/WO2022229342A1/en active Application Filing
- 2022-04-28 CN CN202280029645.0A patent/CN117320556A/zh active Pending
- 2022-04-28 US US18/287,587 patent/US20240188579A1/en active Pending
- 2022-04-28 BR BR112023021397A patent/BR112023021397A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022229342A1 (en) | 2022-11-03 |
US20240188579A1 (en) | 2024-06-13 |
JP2024517153A (ja) | 2024-04-19 |
BR112023021397A2 (pt) | 2023-12-19 |
AU2022263624A1 (en) | 2023-09-21 |
EP4329501A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022200202B2 (en) | Process for production of improved nutritional products containing milk protein and milk saccharides, and products obtained by the process | |
CA2777595C (en) | Allergy treatment using acid treated aqueous whey protein extract | |
AU2017311560A1 (en) | Process for producing infant formula products and acidic dairy products from milk | |
WO2012148269A1 (en) | Method of making a milk protein composition | |
KR20010030665A (ko) | 유장 단백질의 순차적 분리법 및 그의 제제 | |
CN117320556A (zh) | 富含免疫球蛋白的含乳清蛋白的产品 | |
AU2006233196B2 (en) | Enriched milk products | |
CN118450805A (zh) | 富含免疫球蛋白的乳级分 | |
Mulvihill et al. | Production of whey-protein-enriched products | |
WO2022129127A1 (en) | Serum protein concentrate enriched in immunoglobulins | |
CN116829002A (zh) | 具有高免疫球蛋白含量的乳 | |
Gésan-Guiziou | Extraction of Functional Food Ingredients and Nutraceuticals from Dairy | |
WO2024121317A1 (en) | Process for producing a lactoferrin-containing product | |
KR20240108416A (ko) | 혈청 단백질 농축물을 함유하는 유아용 조제식 | |
NZ789463A (en) | Process for production of improved nutritional products containing milk protein and milk saccharides, and products obtained by the process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |